ClinicalTrials.gg
RecruitingNCT07478497Updated Mar 17, 2026

30 Day Insulin Balance Metabolic Health Optimization Protocol

An interventional study of Insulin Balance Formula - Hormetics Weight Optimization System in Insulin, sponsored by Efforia, Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Efforia, Inc · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 149 under way, 2 of them phase 3. Insulin Resistance · United States.

Planned enrollment
158th of 936
100 · median 37
Started
2025
with 27 others
No phase
535 of 1,118
62 open now
Primary completion
2026-10
later than 30 of 146 live
Registered
1,087th of 1,118
by date

Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 158th largest by planned enrollment of the 936 interventional ones that give a count, is one of 28 that started in 2025, is one of 535 with no phase, reaches primary completion later than 30 of the 146 other live ones, and was the 1,087th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,118 studies in Insulin Resistance with a site in United States, or all of them as a file.
02

Study summary

Explore how a dietary supplement can help support healthy insulin levels and its impact on weight, fatigue, and sugar cravings. The Insulin Balance Formula and Hormetics Weight Optimization System is designed for people who are generally healthy and want to support and maintain healthy insulin levels to reach general health goals.

Read the detailed description

Treatment activities:

Daily Activity: Take 3 capsules of the Insulin Balance Supplement daily, ideally 1 capsule before each meal or all at once for convenience. Begin with 1 capsule to assess tolerance and increase to the recommended dose. Take on an empty stomach or with a meal if needed.

Assessments and frequency:

Body Composition Measurement: Complete the assessment as required. PROMIS Sleep Disturbance Scale: Complete the assessment as required. Carbohydrate Craving Questionnaire: Complete the assessment as required. After Meal Hunger \& Fatigue Perception: Complete the assessment as required.

Methodology:

The "Insulin Balance Metabolic Health and Weight Optimization Protocol" is an observational study designed to investigate the effects of a dietary supplement on insulin levels and its subsequent impact on weight management, fatigue, and sugar cravings. In this study, participants serve as their own controls in a single-arm design, a scientific approach known as the "Signal Phase" at Efforia. This trial aims to detect initial positive outcomes that suggest the supplement's effectiveness in promoting metabolic health. During this phase, not only will potential benefits be identified, but it will also gather critical safety data that is currently limited, thereby paving the way for more comprehensive studies in the future.

Participants will partake in a 30-day structured protocol, during which they will incorporate the Insulin Balance Formula into their daily routines alongside a balanced diet. The study is crucial because it addresses the challenges many face in maintaining stable insulin and blood sugar levels, which are essential for metabolic health. By closely monitoring their response to the supplement, participants will provide valuable insights into how this nutritional strategy may enhance energy levels, improve mood consistency, and support healthy weight maintenance. Their role is pivotal in assessing the formula's impact under real-world conditions, generating meaningful data that can inform future interventions.

Throughout the study, participants are encouraged to actively engage and provide honest feedback, ensuring accurate, personalized results. The study emphasizes the importance of privacy and data confidentiality, assuring participants that their information will only be used within the research context. Participants are also advised against introducing new supplements or health interventions during the trial to avoid confounding results. Should any health concerns arise, they are instructed to seek medical attention immediately. The insights gained from this study could significantly advance understanding of nutritional support for managing blood sugar levels, potentially leading to more robust research designs if positive signals are detected.

03

Conditions studied

  • Insulin

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18+ who are generally healthy
  • Ability to read and comprehend English
  • Ability to willfully consent and follow study procedures and tasks

Exclusion criteria

Exclusion Criteria:

  • Individuals with Known Allergies
  • Pregnant or Nursing Individuals
  • Individuals with Insulin Disorders
  • Individuals with GI Disorders
  • Individuals with Mental Health Conditions
  • Individuals with Sleep Disorders
  • Individuals on Medication
  • Athletes under Specific Regulations
  • Individuals Sensitive to Fatigue
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Single Arm longitudinal where participants act as their own control

    Single Arm longitudinal where participants act as their own control

    Dietary Supplement: Insulin Balance Formula - Hormetics Weight Optimization System

Interventions

  • Dietary supplementInsulin Balance Formula - Hormetics Weight Optimization System

    The Insulin Balance Formula, doctor-formulated by Dr. Miriam Mikicki, MD, and Elwin Robinson, combines five potent ingredients, each chosen for its proven ability to combat insulin resistance and support weight loss. Sourced from premium suppliers, these ingredients blend ancient wisdom with modern science: Berberine 500mg Beta Alanine 500 mg Zinc Citrate 15 mg Folate 200 mcg Fenugreek Extract 500 mg

06

What researchers measure

Primary outcomes

  1. Waist Circumference Measured by Flexible Tape Measure

    Waist circumference will be measured in centimeters (cm) using a non-elastic, flexible anthropometric tape measure. Measurements will be taken at the midpoint between the lowest rib and the iliac crest with the participant standing, at the end of a normal exhalation. Two measurements will be obtained, and the average value will be recorded.

    Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)

  2. PROMIS Sleep Disturbance Scale

    Measurement Scale: The PROMIS Sleep Disturbance Scale is a standardized, participant-reported questionnaire consisting of multiple items rated on a 5-point Likert scale (typically ranging from 1 = "Not at all" to 5 = "Very much"). Item responses are summed and converted to a T-score standardized to the general population (mean = 50, standard deviation = 10). Score Interpretation: Higher scores indicate greater sleep disturbance (worse sleep quality), while lower scores indicate better sleep quality.

    Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)

  3. Carbohydrate Craving Questionnaire

    Measurement Scale: The Carbohydrate Craving Questionnaire (CCQ) is a validated, participant-reported questionnaire designed to assess the frequency and intensity of carbohydrate-related cravings. Items are rated on a Likert-type scale (typically ranging from 1 = "Strongly disagree" to 6 or 7 = "Strongly agree," depending on the CCQ version). Item responses are summed to generate a total score. Score Interpretation: Higher total scores indicate greater carbohydrate craving severity, while lower scores indicate lower levels of carbohydrate craving.

    Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)

  4. After Meal Hunger & Fatigue Perception

    This survey aims to understand how individuals perceive different stages of hunger and fatigue after their most recent meal. The respondents are required to select the option that best describes their current state of hunger or fullness, based on a scale of 1 through 10, with 10 being the most favorable. In addition, this survey measures current state of hunger-associated fatigue from "very drowsy" to "very alert" with "very alert" being the most favorable.

    Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30), along with random repetitions 6 times per 2 weeks throughout study.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Insulin Resistance, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 22. This study's planned 12 months is above that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Mar 17, 2026
StartActual
Oct 21, 2025
Primary completionEst.
Oct 21, 2026
CompletionEst.
Oct 21, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478497
Lead sponsor
Efforia, Inc
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Oct 21, 2025
Primary completion
Oct 21, 2026 (estimated)
Completion
Oct 21, 2026 (estimated)
Last update
Mar 17, 2026

Study contacts

Matthew Amsden
Contact
help@efforia.com
(646) 679-2479

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion